Women's College Research Institute, University of Toronto, Toronto, ON.
Beth Israel Deaconness Hospital, Boston, MA, U.S.A.
Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.
The risk of breast cancer in carriers of BRCA1 and BRCA2 mutations is influenced by factors other than the genetic mutation itself. Modifying factors include a woman's reproductive history and family history of cancer. Risk factors are more likely to be present in women with breast cancer than in women without breast cancer, and therefore the risk of cancer in the two breasts should not be independent. It is not clear to what extent modifying factors influence the risk of a first primary or a contralateral breast cancer in BRCA carriers.
We conducted a matched case-control study of breast cancer among 3920 BRCA1 or BRCA2 mutation carriers. We asked whether a past history of breast cancer in the contralateral breast was a risk factor for breast cancer.
After adjustment for age, country of residence, and cancer treatment, a previous cancer of the right breast was found to be a significant risk factor for cancer of the left breast among BRCA1 or BRCA2 carriers (relative risk: 2.1; 95% confidence interval: 1.4 to 3.0; p < 0.0001).
In a woman with a BRCA1 or BRCA2 mutation who is diagnosed with breast cancer, the risk of cancer in the contralateral breast depends on the first diagnosis. That observation supports the hypothesis that there are important genetic or non-genetic modifiers of cancer risk in BRCA carriers. Discovering risk modifiers might lead to greater personalization of risk assessment and management recommendations for BRCA-positive patients.
BRCA1 和 BRCA2 基因突变携带者的乳腺癌风险受到基因突变本身以外的因素的影响。这些修饰因素包括女性的生殖史和癌症家族史。与没有乳腺癌的女性相比,患有乳腺癌的女性更有可能存在这些危险因素,因此双侧乳腺癌的风险不应是独立的。目前尚不清楚修饰因素在多大程度上影响 BRCA 携带者中首次原发性乳腺癌或对侧乳腺癌的风险。
我们对 3920 名 BRCA1 或 BRCA2 基因突变携带者的乳腺癌进行了匹配病例对照研究。我们询问了对侧乳房是否有既往乳腺癌史是否是乳腺癌的危险因素。
在调整年龄、居住国和癌症治疗后,发现右乳腺癌史是 BRCA1 或 BRCA2 携带者中左乳腺癌的显著危险因素(相对风险:2.1;95%置信区间:1.4 至 3.0;p<0.0001)。
在诊断为乳腺癌的 BRCA1 或 BRCA2 基因突变女性中,对侧乳房的癌症风险取决于首次诊断。这一观察结果支持了这样一种假设,即在 BRCA 携带者中存在重要的遗传或非遗传癌症风险修饰因子。发现风险修饰因子可能会导致对 BRCA 阳性患者的风险评估和管理建议更加个性化。